Omada Health, Inc. (OMDA)
Nasdaq · Services-Health Services · Services · CIK 1611115 · fiscal year ends in Dec
Closing price $19.66 on 29 Oct 2026; 52-week range $10.94 to $25.67.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $309.8M
- Net income, last twelve months
- $4.3M
- Earnings per share
- $0.05
- Gross margin
- 68.2%
- Operating margin
- -0.1%
- Net margin
- 1.4%
- Free cash flow
- $22.7M
- Return on equity
- 1.7%
- Market value
- $1.2B
- Price to earnings
- 393.2x
- Cash
- $221.7M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 60.6M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $260.2M | -$12.0M | -$12.8M | -$0.35 | $16.9M | 10-K filed 6 Mar 2026 |
| FY2024 | 31 Dec 2024 | $169.8M | -$43.7M | -$47.1M | -$6.11 | -$34.8M | 10-K filed 6 Mar 2026 |
| FY2023 | 31 Dec 2023 | $122.8M | -$66.0M | -$67.5M | -$9.52 | -$50.2M | 10-K filed 6 Mar 2026 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $87.8M | $5.3M | $0.08 |
| Q1 FY2026 | 31 Mar 2026 | $78.0M | -$3.0M | -$0.05 |
| Q4 FY2025 | 31 Dec 2025 | $75.8M | $5.2M | $0.08 |
| Q3 FY2025 | 30 Sep 2025 | $68.0M | -$3.2M | -$0.06 |
| Q2 FY2025 | 30 Jun 2025 | $61.4M | -$5.3M | -$0.24 |
| Q1 FY2025 | 31 Mar 2025 | $55.0M | -$9.4M | -$1.15 |
| Q3 FY2024 | 30 Sep 2024 | $45.5M | -$9.2M | -$1.18 |
| Q2 FY2024 | 30 Jun 2024 | $41.2M | -$10.7M | -$1.40 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Services | $241.0M | 92.6% |
| Hardware | $19.2M | 7.4% |
Company events
The newest 8-K filings of 8 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 6 Aug 2026 | 8-K | Results, Leadership change | 2.02, 5.02, 9.01 |
| 16 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 5 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 7 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 9 Jun 2025 | 8-K | Bylaws or fiscal year change, Other events | 5.03, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 45 held.
| Filed | Form | Period |
|---|---|---|
| 7 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 16 Jun 2026 | 8-K | 16 Jun 2026 |
| 8 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 28 Apr 2026 | ARS | 31 Dec 2025 |
| 28 Apr 2026 | DEFA14A | – |
| 28 Apr 2026 | DEF 14A | 16 Jun 2026 |
| 6 Mar 2026 | S-8 | – |
| 6 Mar 2026 | 10-K | 31 Dec 2025 |
| 5 Mar 2026 | 8-K | 5 Mar 2026 |
| 12 Jan 2026 | 8-K | 12 Jan 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 5 Oct 2026 | Root Jonathan D, Director | Took pay in stock | 694 | – | – | – | 7 Oct 2026 |
| 5 Oct 2026 | Klapstein Julie D, Director | Took pay in stock | 549 | – | – | – | 7 Oct 2026 |
| 5 Oct 2026 | Fetter Trevor, Director | Took pay in stock | 751 | – | – | – | 7 Oct 2026 |
| 5 Oct 2026 | Hilleman Jeryl L, Director | Took pay in stock | 1,214 | – | – | – | 7 Oct 2026 |
| 1 Oct 2026 | Duffy Sean P., Chief Executive Officer | Sale under a trading plan | 12,944 | $20.61 | $266.8K | 386,908 | 5 Oct 2026 |
| 1 Oct 2026 | Duffy Sean P., Chief Executive Officer | Sale under a trading plan | 4,314 | $20.90 | $90.2K | 382,594 | 5 Oct 2026 |
| 10 Sep 2026 | Duffy Sean P., Chief Executive Officer | Sale under a trading plan | 13,560 | $21.80 | $295.6K | 383,994 | 14 Sep 2026 |
| 10 Sep 2026 | Duffy Sean P., Chief Executive Officer | Sale under a trading plan | 1,400 | $22.59 | $31.6K | 382,594 | 14 Sep 2026 |
| 10 Sep 2026 | Cook Steven L., Chief Financial Officer | Sale under a trading plan | 6,200 | $21.80 | $135.1K | 174,506 | 14 Sep 2026 |
| 10 Sep 2026 | Cook Steven L., Chief Financial Officer | Sale under a trading plan | 600 | $22.52 | $13.5K | 173,906 | 14 Sep 2026 |
| 10 Sep 2026 | Shao Wei-Li, President | Sale under a trading plan | 3,636 | $21.78 | $79.2K | 295,713 | 14 Sep 2026 |
| 10 Sep 2026 | Shao Wei-Li, President | Sale under a trading plan | 400 | $22.53 | $9.0K | 295,313 | 14 Sep 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 1 Oct 2026 | SEAN DUFFY, Director, Officer | 17,258 | $269.4K | 1 Oct 2026 |
| 10 Sep 2026 | WEI-LI SHAO, Officer | 4,036 | $86.8K | 10 Sep 2026 |
| 10 Sep 2026 | Steven Cook, Officer | 6,800 | $146.2K | 10 Sep 2026 |
| 10 Sep 2026 | SEAN DUFFY, Director, Officer | 14,960 | $321.6K | 10 Sep 2026 |
| 9 Sep 2026 | CRAIG GRACEY, Officer | 644 | $14.3K | 9 Sep 2026 |
| 1 Sep 2026 | SEAN DUFFY, Director, Officer | 21,572 | $529.6K | 1 Sep 2026 |
| 12 Aug 2026 | WEI-LI SHAO, Officer | 8,866 | $212.9K | 12 Aug 2026 |
| 11 Aug 2026 | Steven Cook, Officer | 2,715 | $67.8K | 11 Aug 2026 |
| 10 Aug 2026 | CRAIG GRACEY, Officer | 1,042 | $24.7K | 10 Aug 2026 |
| 10 Aug 2026 | SEAN DUFFY, Director, Officer | 12,942 | $306.3K | 10 Aug 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock, Inc. | 13G | 6% | 3.7M |
| 14 Aug 2026 | Divisadero Street Capital Management, LP | 13G amended | 6.3% | 3.8M |
| 14 Aug 2026 | American Century Investment Management, Inc. | 13G | 6.2% | 3.7M |
| 23 Jun 2026 | The Cigna Group | 13G | 5.8% | 3.4M |
| 15 May 2026 | Andreessen Horowitz Fund IV, L.P. | 13G amended | 4.2% | 2.5M |
| 15 May 2026 | Divisadero Street Capital Management, LP | 13G | 9.9% | 5.9M |
| 6 May 2026 | FMR LLC | 13G amended | 5.6% | 3.3M |
| 2 Mar 2026 | Divisadero Street Capital Management, LP | 13G | 8.7% | 5.1M |
| 17 Feb 2026 | Andreessen Horowitz Fund IV, L.P. | 13G amended | 6.1% | 3.5M |
| 17 Feb 2026 | U.S. Venture Partners X, L.P. | 13G amended | 0.2% | 138.1K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 8.3M | +11.99% | 6.71 |
| 30 Sep 2026 | 7.5M | -0.24% | 4.42 |
| 15 Sep 2026 | 7.5M | +30.1% | 5.93 |
| 31 Aug 2026 | 5.7M | -2.46% | 6.46 |
| 14 Aug 2026 | 5.9M | -22.85% | 3.1 |
| 31 Jul 2026 | 7.6M | -4.38% | 5.93 |
| 15 Jul 2026 | 8.0M | +2.43% | 6.87 |
| 30 Jun 2026 | 7.8M | -0.03% | 6.48 |
Funds that hold it
From each fund's latest Form 13F.
172 funds held it at 30 Jun 2026: 98 added and 38 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Revelation Capital Management, LLC | 4,858,034 | $106.6M | -350,000 |
| Divisadero Street Capital Management, LP | 3,799,695 | $83.4M | -2,088,020 |
| American Century Companies Inc. | 3,678,676 | $80.7M | +1,222,367 |
| Cigna Investments Inc. | 3,444,629 | $75.6M | 0 |
| Morgan Stanley | 2,800,887 | $61.5M | +1,334,111 |
| FMR LLC | 2,775,102 | $60.9M | -513,278 |
| NVP Associates, LLC | 2,531,000 | $55.6M | 0 |
| BlackRock, Inc. | 2,222,074 | $48.8M | +317,516 |
| Vanguard Capital Management LLC | 1,926,594 | $42.3M | +117,610 |
| Millennium Management LLC | 1,724,057 | $37.8M | +620,062 |
Peers
Companies in the same industry.
- LifeStance Health Group, Inc. (LFST): revenue $1.6B, market value $5.2B
- Privia Health Group, Inc. (PRVA): revenue $2.4B, market value $2.8B
- GeneDx Holdings Corp. (WGS): revenue $454.4M, market value $2.1B
- Pennant Group, Inc. (PNTG): revenue $1.1B, market value $1.5B
- U S Physical Therapy Inc. (USPH): revenue $812.2M, market value $1.3B
- InnovAge Holding Corp. (INNV): revenue $989.7M, market value $1.3B